From Interview #94
With Emi Gal
How can artificial intelligence make full body MRI screening faster, more affordable, and more accurate? In this compelling interview, Ezra founder and CEO Emi Gal discusses how FDA-approved AI medical devices are transforming MRI scans into a powerful tool for early cancer detection. Gal outlines Ezra's three-tiered AI pipeline—enhancing image quality, assisting radiologists, and translating complex reports into plain language—to deliver a 22-minute, 9 full body MRI scan. Learn how this innovation is helping detect cancer in asymptomatic patients and why younger populations may benefit from early, proactive screening
From Interview #85
With Jason Alan Snyder
Digital twins—AI-powered models based on individual health data—are poised to transform how healthcare predicts, treats, and personalizes care. But Jason Alan Snyder, a technologist and futurist, raises powerful ethical and technical concerns about how these systems are being deployed today. Built from EHRs, lab results, wearables, and even genomics, these digital representations can simulate decisions and even replace human judgment. Yet they are often created without consent or clarity. In this clip, Snyder urges healthcare leaders to reclaim agency over the design and governance of these digital surrogates, emphasizing that the future of AI in healthcare must be rooted in truth, transparency, and trust.
From Interview #88
With Dr. David Fajgenbaum
In this compelling conversation, Dr. David Fajgenbaum describes how his team uses a platform called Matrix, powered by a biomedical knowledge graph, to scan all known relationships between drugs, diseases, and genes. The goal? To apply AI for healthcare data analysis in identifying potential treatments, some of which had been previously overlooked or discarded due to lack of profitability. One powerful example includes the identification of a TNF inhibitor for Castleman disease that led to a lifesaving intervention. Dr. Fajgenbaum emphasizes how this technology doesn't just discover new solutions but also revalidates forgotten ones, shedding light on opportunities to repurpose existing drugs. This showcases the transformative potential of AI predictive analytics in healthcare.
From Interview #76
With Dr. Debra Patt
In this insightful interview, Dr. Debra Patt shares how AI applications in healthcare are transforming the daily realities of clinical care. As a breast medical oncologist and health policy leader, she describes the power of ambient AI scribe technology, which reduces administrative burdens and improves patient communication by instantly generating visit notes. She outlines specific benefits—from more accurate ICD-10 coding to enhanced decision-making in cancer care—that not only help providers get patients the right treatment faster, but also streamline billing and prior authorization. Her perspective offers a grounded, real-world view of "what are the applications of AI in healthcare" today, especially for oncology practices navigating high patient loads and value-based care demands.
From Interview #90
With Adrian Mendes
Adrian Mendes, CEO of Perimeter Medical Imaging, discusses how AI-powered imaging is transforming breast cancer surgery. Leveraging optical coherence tomography (OCT) combined with AI, surgeons can visualize tumor margins at microscopic levels in real-time, reducing the need for repeat surgeries. This innovation offers higher precision in tissue removal, preserving healthy tissue while ensuring complete cancer excision. Mendes also addresses broader applications in head and neck cancers and the role of high-quality data in advancing AI models. The conversation highlights economic benefits, patient psychological relief, and improved access to high-quality surgical outcomes in both urban and rural healthcare settings.
From Interview #89
With Dr. Harvey Castro
Hematologist-oncologist host Dr. Sanjay Juneja sits down with emergency physician and AI advisor Dr. Harvey Castro to demystify agentic AI in healthcare. Castro explains how clinician and patient digital twins could safely scale expertise, reduce ER bottlenecks, and improve decisions when paired with human oversight. The discussion compares build-versus-buy choices for ambient scribing and other use cases, notes when open-source models can lower costs, and outlines how federated learning lets hospitals benefit from broader data without exposing PHI. They also tackle workforce shortages, forecasting near-term wins from ambient documentation, monitoring at home, and culturally aware guidance at the bedside. Throughout, Castro stresses pragmatic guardrails—HIPAA, FDA pathways, and clinician validation—to mitigate hallucinations and bias. For leaders planning an AI strategy, the conversation offers a clear, reader-first roadmap that highlights ai agents in healthcare while staying focused on patient outcomes.
From Interview #88
With Dr. David Fajgenbaum
In this insightful interview, Dr. David Fajgenbaum, Co-founder of Every Cure, shares how artificial intelligence is revolutionizing rare disease research and treatment. Drawing from his own groundbreaking work in drug repurposing and precision medicine, Dr. Fajgenbaum explains how AI tools can rapidly identify therapeutic opportunities hidden in existing medical data. He discusses the challenges of rare disease diagnosis, the importance of cross-disease data analysis, and the potential of AI to accelerate life-saving discoveries. Through a mix of personal experience and scientific expertise, he paints a compelling vision for how AI could reshape the landscape of rare disease care and improve patient outcomes worldwide.
From Interview #86
With Dr. Euan Ashley
In this full interview, Dr. Euan Ashley, Chair of the Department of Medicine at Stanford, shares how preventive cardiology is being transformed by remote monitoring, AI, and wearable technologies. Ashley highlights how early detection through wearable devices can identify subtle changes in cardiac function before symptoms appear, enabling timely interventions that prevent severe events. He discusses advances in remote cardiac monitoring, AI-powered risk prediction, and how continuous data streams are improving both individualized care and population health. This conversation offers a compelling vision for integrating cutting-edge technology into preventive cardiovascular medicine.
From Interview #80
With Dr. Azra Raza
Dr. Azra Raza, Professor of Medicine at Columbia University, challenges the cancer research community to shift focus from treating late-stage disease to detecting cancer at the 'first cell' stage. Drawing on decades of clinical work and a unique repository of 60,000 patient samples, she outlines how AI-powered, continuous monitoring could revolutionize early detection. Dr. Raza critiques the limitations of current models and screening methods, advocating for human-based research and proactive monitoring to prevent cancer before it requires invasive treatment. Her vision combines multi-omics analysis with implantable biosensors to identify biomarkers long before cancer reaches stage one, aiming to reduce suffering and improve outcomes.
From Interview #77
With Tom Neyarapally
In this full interview, Tom Neyarapally, CEO and Co-Founder of Archetype Therapeutics, discusses the transformative role of AI in drug development. He explores how generative AI is accelerating drug discovery, enabling drug repurposing, and reshaping therapeutic innovation. Neyarapally provides a forward-looking perspective on the future of AI in healthcare, drawing from his deep expertise and hands-on leadership in the biotech industry.